Karl T Johnson1, Gavin J Churchyard2, Hojoon Sohn3, David W Dowdy3. 1. Krieger School of Arts and Sciences, Johns Hopkins University, Baltimore, Maryland. 2. Aurum Health, Johannesburg, South Africa. 3. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Abstract
Background: A short-course regimen of 3 months of weekly rifapentine and isoniazid (3HP) has recently been recommended by the World Health Organization as an alternative to at least 6 months of daily isoniazid (isoniazid preventive therapy [IPT]) for prevention of tuberculosis (TB). The contexts in which 3HP may be cost-effective compared to IPT among people living with human immunodeficiency virus are unknown. Methods: We used a Markov state transition model to estimate the incremental cost-effectiveness of 3HP relative to IPT in high-burden settings, using a cohort of 1000 patients in a Ugandan HIV clinic as an emblematic scenario. Cost-effectiveness was expressed as 2017 US dollars per disability-adjusted life year (DALY) averted from a healthcare perspective over a 20-year time horizon. We explored the conditions under which 3HP would be considered cost-effective relative to IPT. Results: Per 1000 individuals on antiretroviral therapy in the reference scenario, treatment with 3HP rather than IPT was estimated to avert 9 cases of TB and 1 death, costing $9402 per DALY averted relative to IPT. Cost-effectiveness depended strongly on the price of rifapentine, completion of 3HP, and prevalence of latent TB. At a willingness to pay of $1000 per DALY averted, 3HP is likely to be cost-effective relative to IPT only if the price of rifapentine can be greatly reduced (to approximately $20 per course) and high treatment completion (85%) can be achieved. Conclusions: 3HP may be a cost-effective alternative to IPT in high-burden settings, but cost-effectiveness depends on the price of rifapentine, achievable completion rates, and local willingness to pay.
Background: A short-course regimen of 3 months of weekly rifapentine and isoniazid (3HP) has recently been recommended by the World Health Organization as an alternative to at least 6 months of daily isoniazid (isoniazid preventive therapy [IPT]) for prevention of tuberculosis (TB). The contexts in which 3HP may be cost-effective compared to IPT among people living with human immunodeficiency virus are unknown. Methods: We used a Markov state transition model to estimate the incremental cost-effectiveness of 3HP relative to IPT in high-burden settings, using a cohort of 1000 patients in a Ugandan HIV clinic as an emblematic scenario. Cost-effectiveness was expressed as 2017 US dollars per disability-adjusted life year (DALY) averted from a healthcare perspective over a 20-year time horizon. We explored the conditions under which 3HP would be considered cost-effective relative to IPT. Results: Per 1000 individuals on antiretroviral therapy in the reference scenario, treatment with 3HP rather than IPT was estimated to avert 9 cases of TB and 1 death, costing $9402 per DALY averted relative to IPT. Cost-effectiveness depended strongly on the price of rifapentine, completion of 3HP, and prevalence of latent TB. At a willingness to pay of $1000 per DALY averted, 3HP is likely to be cost-effective relative to IPT only if the price of rifapentine can be greatly reduced (to approximately $20 per course) and high treatment completion (85%) can be achieved. Conclusions: 3HP may be a cost-effective alternative to IPT in high-burden settings, but cost-effectiveness depends on the price of rifapentine, achievable completion rates, and local willingness to pay.
Authors: Florian M Marx; Ted Cohen; Nicolas A Menzies; Joshua A Salomon; Grant Theron; Reza Yaesoubi Journal: Lancet Glob Health Date: 2020-09 Impact factor: 26.763
Authors: Jon C Emery; Alexandra S Richards; Katie D Dale; C Finn McQuaid; Richard G White; Justin T Denholm; Rein M G J Houben Journal: Proc Biol Sci Date: 2021-01-20 Impact factor: 5.349
Authors: Olivia Ferguson; Youngji Jo; Jeff Pennington; Karl Johnson; Richard E Chaisson; Gavin Churchyard; David Dowdy Journal: J Int AIDS Soc Date: 2020-10 Impact factor: 5.396
Authors: Jennifer M Ross; Anani Badje; Molebogeng X Rangaka; A Sarah Walker; Adrienne E Shapiro; Katherine K Thomas; Xavier Anglaret; Serge Eholie; Delphine Gabillard; Andrew Boulle; Gary Maartens; Robert J Wilkinson; Nathan Ford; Jonathan E Golub; Brian G Williams; Ruanne V Barnabas Journal: Lancet HIV Date: 2021-01 Impact factor: 12.767